Differential outcomes from metabolic ratios in the identification of CYP2D6 phenotypes–focus on venlafaxine and O-desmethylvenlafaxine

被引：0
作者：
Mani Kandasamy
P. Srinivas
Kala Subramaniam
Sandhya Ravi
James John
Radha Shekar
Nuggehally Srinivas
Saral Thangam
机构：
[1] Lotus Labs,Biometrics
[2] Lotus Labs Pvt. Ltd.,Bioanalytical
[3] Lotus Labs Pvt. Ltd.,Clinical
[4] Suramas Biopharm,Drug Development
来源：
European Journal of Clinical Pharmacology | 2010年 / 66卷
关键词：
CYP2D6; Venlafaxine; O-desmethyvenlafaxine; Pharmacokinetics; Bioavailability;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：879 / 887
页数：8
相关论文
共 50 条
  • [11] CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine
    Shams, M. E. E.
    Arneth, B.
    Hiemke, C.
    Dragicevic, A.
    Mueller, M. J.
    Kaiser, R.
    Lackner, K.
    Haertter, S.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2006, 31 (05) : 493 - 502
  • [12] An Observational Study of Venlafaxine and CYP2D6 in Clinical Practice
    Rolla, R.
    Gramaglia, Carla
    Dalo, Valentina
    Ressico, Francesca
    Prosperini, Pierluigi
    Vidali, Matteo
    Meola, Silvia
    Pollarolo, Paola
    Bellomo, Giorgio
    Torre, Eugenio
    Zeppegno, Patrizia
    CLINICAL LABORATORY, 2014, 60 (02) : 225 - 231
  • [13] The influences of CYP2D6 genotypes and drug interactions on the pharmacokinetics of venlafaxine: exploring predictive biomarkers for treatment outcomes
    Jiang, Fen
    Kim, Hae-Deun
    Na, Han-Sung
    Lee, Seok-Yong
    Seo, Doo-Won
    Choi, Jong-Yeol
    Ha, Ji-Hye
    Shin, Hee-Jung
    Kim, Young-Hoon
    Chung, Myeon-Woo
    PSYCHOPHARMACOLOGY, 2015, 232 (11) : 1899 - 1909
  • [14] The influences of CYP2D6 genotypes and drug interactions on the pharmacokinetics of venlafaxine: exploring predictive biomarkers for treatment outcomes
    Fen Jiang
    Hae-Deun Kim
    Han-Sung Na
    Seok-Yong Lee
    Doo-Won Seo
    Jong-Yeol Choi
    Ji-Hye Ha
    Hee-Jung Shin
    Young-Hoon Kim
    Myeon-Woo Chung
    Psychopharmacology, 2015, 232 : 1899 - 1909
  • [15] Measurement of Hepatic CYP3A4 and 2D6 Activity Using Radioiodine-Labeled O-Desmethylvenlafaxine
    Mizutani, Asuka
    Kobayashi, Masato
    Aibe, Riku
    Muranaka, Yuka
    Nishi, Kodai
    Kitamura, Masanori
    Suzuki, Chie
    Nishii, Ryuichi
    Shikano, Naoto
    Magata, Yasuhiro
    Ishida, Yasushi
    Kunishima, Munetaka
    Kawai, Keiichi
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (19)
  • [16] Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers
    Fukuda, T
    Yamamoto, I
    Nishida, Y
    Zhou, Q
    Ohno, M
    Takada, K
    Azuma, J
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 47 (04) : 450 - 453
  • [17] Impact of CYP2D6 on venlafaxine metabolism in Trinidadian patients with major depressive disorder
    Jaime, Lazara Karelia Montane
    Paul, Jeffrey
    Lalla, Anthony
    Legall, George
    Gaedigk, Andrea
    PHARMACOGENOMICS, 2018, 19 (03) : 197 - 212
  • [18] Effects of CYP2D6 Genotypes on Venlafaxine Metabolism in Japanese Psychiatric Patients With Depression
    Komahashi-Sasaki, Hazuki
    Yasui-Furukori, Norio
    Sasaki, Taro
    Shinozaki, Masataka
    Hayashi, Yuki
    Kato, Kazuko
    Inoue, Yoshimasa
    Tsuchimine, Shoko
    Watanabe, Takashi
    Sugawara, Norio
    Shimoda, Kazutaka
    THERAPEUTIC DRUG MONITORING, 2021, 43 (05) : 681 - 687
  • [19] Olanzapine disposition in humans is unrelated to CYP1A2 and CYP2D6 phenotypes
    Bassirat M.
    Khalil Z.
    European Journal of Clinical Pharmacology, 2001, 57 (6) : 493 - 497
  • [20] Olanzapine disposition in humans is unrelated to CYP1A2 and CYP2D6 phenotypes
    Hägg, S
    Spigset, O
    Lakso, HÅ
    Dahlqvist, R
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 57 (6-7) : 493 - 497
12345